Propofol and sedation in patients with coronavirus disease
- PMID: 32732086
- PMCID: PMC7299857
- DOI: 10.1016/j.ajem.2020.06.023
Propofol and sedation in patients with coronavirus disease
Keywords: Coronavirus disease; Propofol; Sedatives.
Conflict of interest statement
Declaration of Competing Interest The author declares no conflict of interest.
Comment in
-
The authors' response: Propofol and sedation in patients with coronavirus disease 2019.Am J Emerg Med. 2021 Apr;42:251. doi: 10.1016/j.ajem.2020.06.022. Epub 2020 Jun 18. Am J Emerg Med. 2021. PMID: 32611498 Free PMC article. No abstract available.
Comment on
-
Neuroleptic malignant syndrome in patients with COVID-19.Am J Emerg Med. 2020 Oct;38(10):2243.e1-2243.e3. doi: 10.1016/j.ajem.2020.05.042. Epub 2020 May 22. Am J Emerg Med. 2020. PMID: 32473756 Free PMC article.
References
-
- Cao L., Xu L., Huang B., Wu L. Propofol increases angiotensin-converting enzyme 2 expression in human pulmonary artery endothelial cells. Pharmacology. 2012;90:342–347. - PubMed
-
- Zhang L., Wang J., Liang J., Feng D., Deng F., Yang Y., et al. Propofol prevents human umbilical vein endothelial cell injury from Ang II-induced apoptosis by activating the ACE2-(1-7)-mas axis and eNOS phosphorylation. PLoS One. 2018 Jul 11;13 doi: 10.1371/journal.pone.0199373. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical